Intelligent Bio Solutions Completes Interference Study for FDA Clearance
Event summary
- Intelligent Bio Solutions completed an interference study for its Intelligent Fingerprinting Drug Screening System, evaluating the impact of everyday substances like hand creams and oils on test accuracy.
- The study was conducted with CenExel Clinical Research following FDA guidelines and ICH GCP standards.
- Data analysis is underway, with independent verification via LC-MS/MS analysis.
- The company remains on track to submit its FDA 510(k) package in H2 2026 for U.S. market entry.
The big picture
Intelligent Bio Solutions is advancing its non-invasive drug screening technology toward U.S. market entry, a move that could disrupt traditional workplace drug testing methods. The completion of this interference study is a critical step in securing FDA clearance, positioning the company to tap into a lucrative market dominated by employers in safety-critical industries.
What we're watching
- Regulatory Timeline
- Whether the company can maintain its H2 2026 submission timeline for FDA clearance.
- Market Penetration
- The pace at which Intelligent Bio Solutions can enter the multi-billion-dollar U.S. drug screening market post-clearance.
- Technology Validation
- How the interference study results will impact the perceived reliability of the fingerprinting system among potential customers.